Reviewing Schrodinger (NASDAQ:SDGR) & Mitesco (OTCMKTS:MITI)

Schrodinger (NASDAQ:SDGR) and Mitesco (OTCMKTS:MITI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares Schrodinger and Mitesco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.37%	-29.47%	-14.69%
Mitesco	-7,638.20%	N/A	-2,270.77%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Schrodinger and Mitesco, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1	4	4	0	2.33
Mitesco	0	0	0	0	0.00

Schrodinger presently has a consensus price target of $20.50, indicating a potential upside of 79.43%. Given Schrodinger’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Schrodinger is more favorable than Mitesco.

Earnings & Valuation

This table compares Schrodinger and Mitesco”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87 million	3.30	-$103.26 million	($1.42)	-8.05
Mitesco	$40,000.00	50.60	-$2.51 million	($0.14)	-0.71

Mitesco has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Mitesco, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Schrodinger has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Mitesco has a beta of 5.6, suggesting that its share price is 460% more volatile than the S&P 500.

Institutional & Insider Ownership

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 0.0% of Mitesco shares are held by institutional investors. 21.0% of Schrodinger shares are held by insiders. Comparatively, 4.9% of Mitesco shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Schrodinger beats Mitesco on 8 of the 14 factors compared between the two stocks.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

About Mitesco

Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.